FDA Approves Pimjetmi for Rare Tumor Treatment

The U.S. FDA has approved Pimjetmi (pimicotinib), a CSF-1R inhibitor, as a systemic treatment for adults with symptomatic tenosynovial giant cell tumour (TGCT) where surgery is not ideal. This marks Abbisko Therapeutics' first innovative medicine to achieve global commercialization, offering a new therapeutic option for patients with this rare condition.